An overview of the clinical pharmacokinetics of nabumetone.
Nabumetone is a new, nonacidic, nonsteroidal antiinflammatory drug. At least 80% of nabumetone is absorbed, and food, milk, and aluminum antacids increase the rate, but not the extent, of absorption. It is rapidly metabolized in the liver to 6-methoxy-2-naphthylacetic acid (6MNA), the major circulating active metabolite. At steady state, the time to maximum plasma concentration for 6MNA is 1 to 4 h. 6MNA has a very low clearance rate and long half-life (about 24 h). In general, steady state plasma concentrations of 6MNA increase in proportion with increases in the dose of nabumetone administered. Steady state plasma concentrations of 6MNA in the elderly are slightly higher than in healthy volunteers; however, this does not appear to be clinically significant. Preliminary studies in patients with impaired renal function indicate that the pharmacokinetics are not altered in patients with mild to moderate disease.
Hyneck
M L
ML
SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism; D000863:Antacids / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000493:pharmacokinetics / Q000652:urine; D002074:Butanones / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D004435:Eating; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism; D000077430:Nabumetone
D000863:Antacids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D000077430:Nabumetone